ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2023-53734

dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

Published Dec 4, 2025 · catalog updated Apr 7, 2026 · dawa-pharma-1.0 allows unauthenticated attackers

Last checked Oct 27, 2026. A connected source was read within the last 7 days.

Check if you run it

No confirmed exploitation is on record for CVE-2023-53734. EPSS is 0.53%. Act only if a listed version of dawa-pharma-1.0 allows unauthenticated attackers is installed.

Gaps on this record

  • The stored product name is a package slug. The name on this page is taken from the title (dawa-pharma-1.0 allows unauthenticated attackers).
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
High8.7
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.53%
Remediation
Vendor / distro source
Affected products
vendor mayurik dawa-pharma 1.0-2022

dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • vendor mayurik dawa-pharma 1.0-20221.0-2022

How to fix CVE-2023-53734

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2023-53734. EPSS is 0.53%. Act only if a listed version of dawa-pharma-1.0 allows unauthenticated attackers is installed.

Which versions are affected?

Compare what you have installed with mayurik dawa-pharma 1.0-2022 1.0-2022. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

No weakness class is stored. EPSS 0.53%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

Timeline

Detection, updates, and resolution for this record.

  1. Dec 4, 2025 · EUVD

    Detected

    dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

  2. Apr 7, 2026 · EUVD

    Updated

    dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

Sources

  • CVE.orgVulnerability recordCVE-2023-53734

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2023-53734

    30-day exploitation probability 0.53%

    first.org
  • EUVDVulnerability recordEUVD-2025-201278

    dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

    euvd.enisa.europa.eu

References

Freshness

Last verified in this catalog Oct 26, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.

  • CVE.orgOct 27, 2026
  • FIRST EPSSOct 26, 2026
  • EUVDOct 26, 2026